skip to main content

Potential of C-Phenylcalix[4]Resorcinarene Epoxide Compound as Drug Delivery Agent in Breast Cancer Cells MCF-7

Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, Indonesia

Received: 22 Oct 2021; Revised: 20 Feb 2022; Accepted: 24 Feb 2022; Published: 31 Mar 2022.
Open Access Copyright 2022 Jurnal Kimia Sains dan Aplikasi under http://creativecommons.org/licenses/by-sa/4.0.

Citation Format:
Cover Image
Abstract

Cancer therapy through conventional chemotherapy has been widely applied; however, one of the main disadvantages of chemotherapy is the non-selective targeting of cancer cells which causes various adverse side effects. The development of drug delivery agents that are more selective and effective in cancer therapy needs to be performed so that the drugs have a therapeutic effect and minimize side effects. In this study, the compound C-phenylcalyx[4]resorcinarene epoxide (CFKRE) has acted as a drug delivery agent because it can form host complex interactions with ligands. The CFKRE compound was synthesized through two reaction steps: the condensation and alkylation reactions of the epoxide. The structure was analyzed using FTIR, 1H-, and 13C-NMR spectrophotometers and then tested for in vitro cytotoxicity using the MTT assay. The results showed that 70% yield of CFKRE was obtained. Molecular docking analysis of CFKRE compounds against PDGFR and EGFR proteins showed high binding energy compared to conventional chemotherapeutic agents. Molecular dynamic studies showed that CFKRE compounds could form a host-ligand complex with a −350.4 kcal/mol binding energy. Cytotoxic assay of CFKRE compound against MCF-7 breast cancer cells and Vero cells gave IC50 values of 4.04 and 29.59 μg/mL, respectively. These results indicated that CFKRE compounds are not toxic and have the potential to be utilized as new candidates for drug delivery agents.

Fulltext View|Download
Keywords: C-phenylcalyx[4]resorcinarene epoxide; drug delivery; breast cancer
Funding: Universitas Gadjah Mada

Article Metrics:

  1. Christine L. Chaffer, Robert A. Weinberg, A perspective on cancer cell metastasis, Science, 331, 6024, (2011), 1559-1564 https://doi.org/10.1126/science.1203543
  2. Rebecca S. Y. Wong, Apoptosis in cancer: from pathogenesis to treatment, Journal of Experimental & Clinical Cancer Research, 30, 1, (2011), 1-14 https://doi.org/10.1186/1756-9966-30-87
  3. Bruce A. Chabner, Thomas G. Roberts, Chemotherapy and the war on cancer, Nature Reviews Cancer, 5, 1, (2005), 65-72 https://doi.org/10.1038/nrc1529
  4. Sudipta Senapati, Arun Kumar Mahanta, Sunil Kumar, Pralay Maiti, Controlled drug delivery vehicles for cancer treatment and their performance, Signal Transduction and Targeted Therapy, 3, 1, (2018), 1-19 https://doi.org/10.1038/s41392-017-0004-3
  5. Jessica J. Tao, Kala Visvanathan, Antonio C. Wolff, Long term side effects of adjuvant chemotherapy in patients with early breast cancer, The Breast, 24, (2015), S149-S153 https://doi.org/10.1016/j.breast.2015.07.035
  6. Karol Bukowski, Mateusz Kciuk, Renata Kontek, Mechanisms of multidrug resistance in cancer chemotherapy, International Journal of Molecular Sciences, 21, 9, (2020), 3233 https://doi.org/10.3390/ijms21093233
  7. Oktay Tacar, Pornsak Sriamornsak, Crispin R. Dass, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems, Journal of Pharmacy and Pharmacology, 65, 2, (2013), 157-170 https://doi.org/10.1111/j.2042-7158.2012.01567.x
  8. Dengguo Wei, Xiaolu Jiang, Lu Zhou, Jing Chen, Zheng Chen, Chong He, Kun Yang, Ying Liu, Jianfeng Pei, Luhua Lai, Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching, Journal of Medicinal Chemistry, 51, 24, (2008), 7882-7888 https://doi.org/10.1021/jm8010096
  9. Emmy Yuanita, Pranowo Harno Dwi, Mustofa Mustofa, Swasono Respati Tri, Jufriza Syahri, Jumina Jumina, Synthesis, characterization and molecular docking of chloro-substituted hydroxyxanthone derivatives, Chemistry Journal of Moldova, 14, 1, (2019), 68-76 http://dx.doi.org/10.19261/cjm.2018.520
  10. Jose Baselga, Why the epidermal growth factor receptor? The rationale for cancer therapy, The Oncologist, 7, S4, (2002), 2-8 https://doi.org/10.1634/theoncologist.7-suppl_4-2
  11. Mengrui Liu, Hongliang Du, Wenjia Zhang, Guangxi Zhai, Internal stimuli-responsive nanocarriers for drug delivery: Design strategies and applications, Materials Science and Engineering: C, 71, (2017), 1267-1280 https://doi.org/10.1016/j.msec.2016.11.030
  12. Zhe Wang, Xiangping Deng, Jinsong Ding, Wenhu Zhou, Xing Zheng, Guotao Tang, Mechanisms of drug release in pH-sensitive micelles for tumour targeted drug delivery system: A review, International Journal of Pharmaceutics, 535, 1-2, (2018), 253-260 https://doi.org/10.1016/j.ijpharm.2017.11.003
  13. Sandeep J. Sonawane, Rahul S. Kalhapure, Thirumala Govender, Hydrazone linkages in pH responsive drug delivery systems, European Journal of Pharmaceutical Sciences, 99, (2017), 45-65 https://doi.org/10.1016/j.ejps.2016.12.011
  14. Yue Zhou, Hui Li, Ying-Wei Yang, Controlled drug delivery systems based on calixarenes, Chinese Chemical Letters, 26, 7, (2015), 825-828 https://doi.org/10.1016/j.cclet.2015.01.038
  15. Anis Abdul Karim, Qingqing Dou, Zibiao Li, Xian Jun Loh, Emerging supramolecular therapeutic carriers based on host–guest interactions, Chemistry–An Asian Journal, 11, 9, (2016), 1300-1321 https://doi.org/10.1002/asia.201501434
  16. Fazel Nasuhi Pur, Karim Akbari Dilmaghani, Calixplatin: novel potential anticancer agent based on the platinum complex with functionalized calixarene, Journal of Coordination Chemistry, 67, 3, (2014), 440-448 https://doi.org/10.1080/00958972.2014.890718
  17. Jingxin Mo, Paul K. Eggers, Zhi-Xiang Yuan, Colin L. Raston, Lee Yong Lim, Paclitaxel-loaded phosphonated calixarene nanovesicles as a modular drug delivery platform, Scientific Reports, 6, 1, (2016), 1-12 https://doi.org/10.1038/srep23489
  18. M. D. Shah, Y. K. Agrawal, Calixarene: A new architecture in the analytical and pharmaceutical technology, Journal of Scientific and Industrial Research (JSIR), 71, (2012), 21-26
  19. Ângelo de Fátima, Sergio A. Fernandes, Adão Aparecido Sabino, Calixarenes as new platforms for drug design, Current Drug Discovery Technologies, 6, 2, (2009), 151-170 http://dx.doi.org/10.2174/157016309788488302
  20. Ali Yousaf, Shafida Abd Hamid, Noraslinda M. Bunnori, A. A. Ishola, Applications of calixarenes in cancer chemotherapy: facts and perspectives, Drug Design, Development and Therapy, 9, (2015), 2831 https://doi.org/10.2147/DDDT.S83213
  21. Rodrigo Galindo-Murillo, María Eugenia Sandoval-Salinas, Joaquín Barroso-Flores, In silico design of monomolecular drug carriers for the tyrosine kinase inhibitor drug imatinib based on calix-and thiacalix [n] arene host molecules: a DFT and molecular dynamics study, Journal of Chemical Theory and Computation, 10, 2, (2014), 825-834 https://doi.org/10.1021/ct4004178

Last update:

  1. Multifaceted Characterization and Therapeutic Evaluation of Co-precipitated Cobalt Ferrite Nanoparticles for Magnetic Hyperthermia Cancer Therapy

    R. Jafrin Reena, N. Arunai Nambi Raj. Journal of Medical Physics, 49 (4), 2024. doi: 10.4103/jmp.jmp_57_24
  2. Oliveramine: An Isolated Alkaloid from Fagraea fragrans (Tembesu) Bark

    Dasril Basir, Jefri Liasta, Annisa Amelia, Miksusanti Miksusanti, Susilawati Susilawati. Jurnal Kimia Sains dan Aplikasi, 25 (7), 2022. doi: 10.14710/jksa.25.7.264-269
  3. The Journey of Natural Products: From Isolation Stage to Drug’s Approval in Clinical Trials

    Yehezkiel Steven Kurniawan, Tantiana Indriani, Hanif Amrulloh, Langit Cahya Adi, Arif Cahyo Imawan, Krisfian Tata Aneka Priyangga, Ervan Yudha. Bioactivities, 1 (2), 2023. doi: 10.47352/bioactivities.2963-654X.190
  4. Fight for Cancer Diseases using Natural Compounds and Their Semisynthetic Derivatives

    Yehezkiel Steven Kurniawan, Kasta Gurning, Iksen Iksen, Ahmad Bikharudin. Bioactivities, 2 (2), 2024. doi: 10.47352/bioactivities.2963-654X.221

Last update: 2024-12-27 03:03:49

No citation recorded.